Clinical trials: Chidamide
HIV-1-infection
A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir
To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption.
- Trial name
- NCT04985890
- Testing
- UB-421, UB-421+chidamide
- Volunteers
- 20 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Breast Cancer
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.
- Trial name
- NCT06547476
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
- Volunteers
- 40 people
- Sponsor
- Guangdong Provincial People's Hospital
Sarcoma
Chidamide Combined With Toripalimab in Sarcoma
Soft tissue sarcoma is a relatively rare malignant tumor with an incidence of about 1-2/100,000. The best way to obtain evidence-based medical evidence is to participate in clinical trials with new drugs (especially targeted…
- Trial name
- NCT04025931
- Testing
- chidamide and toripalimab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Sun Yat-sen University
Peripheral T-Cell Lymphoma
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
This is a prospective single-arm, multicenter, phase Ib clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.
- Trial name
- NCT05083208
- Testing
- Parsaclisib, Chidamide
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Henan Cancer Hospital
T Lymphoblastic Leukemia/Lymphoma
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Clinical Study on the Safety and Effectiveness of low-dose chidamide maintenance therapy after allogeneic hematopoietic stem cell transplantation for T-cell acute lymphoblastic leukemia or T-cell lymphomas.
- Trial name
- NCT05991973
- Testing
- Chidamide
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang University
Immune Checkpoint Inhibitor, Chemotherapy Effect
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.
- Conditions
- Immune Checkpoint Inhibitor, Chemotherapy Effect, Epigenetic Disorder, NK/T-cell Lymphoma of Nasal Cavity
- Trial name
- NCT04414969
- Testing
- Anti-PD-1 antibody+Peg-Asparaginase+Chidamide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Hunan Cancer Hospital
B-cell Non-Hodgkin's Lymphoma
Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's…
- Trial name
- NCT03105596
- Testing
- Chidamide plus DICE Regimen
- Volunteers
- 46 people
- Sponsor
- Peking University
Breast Cancer
Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Triple-negative breast cancer has always been a difficult problem in clinical practice because of its young onset age, high aggressiveness, no clear therapeutic target and poor clinical prognosis.
- Trial name
- NCT05749575
- Testing
- Chidamide Plus Toripalimab Plus Paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
Currently, treatment options for Epstein-Barr virus (EBV) infection are limited, with unsatisfactory efficacy and no established standard therapy.
- Conditions
- Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133776
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.
- Trial name
- NCT05320640
- Testing
- Chidamide, Decitabine, Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Advanced Breast Cancer
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
This is a Open-label study of chidamide in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who have received no or only one line of…
- Trial name
- NCT05047848
- Testing
- Chidamide, Fulvestrant
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Colorectal Cancer Metastatic
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced…
- Trial name
- NCT06682247
- Testing
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
- Volunteers
- 200 people
- Sponsor
- Feng Wang
Liver Cancer
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
The purpose of this study is to explore the safety and tolerability of chidamide in combination with Sintilimab and bevacizumab in patients with advanced liver cancer, to determine the recommended dose for this combination…
- Trial name
- NCT06408623
- Testing
- chidamide combined with Sintilimab and bevacizumab
- Volunteers
- 48 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Microsatellite-stable Colorectal Cancer
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab versus standard second-line FOLFIRI + bevacizumab therapy in subjects with…
- Trial name
- NCT05768503
- Testing
- Experimental drug, Control Rx
- Where
- 12 sites in China
- Volunteers
- 176 people
- Sponsor
- Sun Yat-sen University
Triple-negative Breast Cancer
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer
The goal of this clinical trial is to evaluate therapeutic efficacy and safety of Chidamide combined with Cisplatin for relapsed or metastatic triple-negative breast cancer.
- Trial name
- NCT04192903
- Testing
- Chidamide combined with Cisplatin
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Fudan University
HR+/HER2- Advanced Breast Cancer
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
A phase 1B study to explore the maximum tolerated dose (MTD) of dalpiciclib + chidamide in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy
- Trial name
- NCT05586841
- Testing
- Dalpiciclib, Chidamide
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Beijing 302 Hospital
Lymphoma
Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma
Currently, combined chemotherapy (CT) and radiation (RT) is recognized as the standard treatment for high-risk early-stage NKTCL.
- Trial name
- NCT04511351
- Testing
- Chidamide
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Chinese Academy of Medical Sciences
Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
The purpose of this study is to explore the efficacy and safety of chidamide combined with sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Neuroendocrine Neoplasm
- Trial name
- NCT05113355
- Testing
- Chidamide, Sintilimab
- Where
- 2 sites in China
- Volunteers
- 23 people
- Sponsor
- Peking Union Medical College Hospital
Relapsed or Refractory DLBCL
Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)
To assess the efficacy and safety of Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in the Treatment of Relapsed or Refractory DLBCL
- Trial name
- PCR (NCT05115409)
- Testing
- Anti-PD-1 Antibody Plus Chidamide and Rituximab
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
Peripheral Blood Stem Cell Transplantation
Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma Underwenting Haploidenticl…
- Trial name
- NCT05075681
- Testing
- Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital